Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors

Jayesh Desai, Sridhar Shankar, Michael Heinrich, Jonathan A. Fletcher, Christopher D. Fletcher, Judi Manola, Jeffrey A. Morgan, Christopher Corless, Suzanne George, Kemal Tuncali, Stuart G. Silverman, Annick D. Van Den Abbeele, Eric Van Sonnenberg, George D. Demetri

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Purpose: Resistance to imatinib mesylate is emerging as a clinical challenge in patients with metastatic gastrointestinal stromal tumors (GIST). Novel patterns of progression have been noted in a number of these patients. The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression. Experimental Design: Patients with metastatic GIST treated with imatinib were followed with serial computed tomography/magnetic resonance imaging and [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Where feasible, biopsies were done to document disease progression. Results: A total of 89 patients were followed for a median of 43 months. Forty-eight patients developed progressive disease. A unique "resistant clonal nodule" pattern (defined as a new enhancing nodular focus enclosed within a preexisting tumor mass) was seen in 23 of 48 patients and was thought to represent emergence of clones resistant to imatinib. Nodules were demonstrable a median of 5 months (range, 0-13 months) before objective progression defined by tumor size criteria and were the first sign of progression in 18 of 23 patients. Median survival among patients whose first progression was nodular was 35.1 months, compared with 44.6 months for patients whose first progression met Southwest Oncology Group criteria (P = 0.31). Comparative tumor biopsies were done in 10 patients at baseline and from progressing nodules. Genotypic analyses of KIT and PDGFRA kinases were done, revealing new activating kinase mutations in 80% (8 of 10) of these patients. Conclusion: The resistant clonal nodule is a unique pattern of disease progression seen in patients with GISTs after an initial response to imatinib and reflects the emergence of imatinib-resistant clones. Conventional tumor measurements (Southwest Oncology Group/Response Evaluation Criteria in Solid Tumors) do not detect this subtle finding. A new enhancing nodule growing within a preexisting tumor mass should be classified as a new lesion and be regarded, at least, as partial progression of GIST.

Original languageEnglish (US)
Pages (from-to)5398-5405
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number18
DOIs
StatePublished - Sep 15 2007

Fingerprint

Clonal Evolution
Gastrointestinal Stromal Tumors
Disease Progression
Neoplasms
Imatinib Mesylate
Phosphotransferases
Clone Cells
Biopsy
Deoxyglucose
Positron-Emission Tomography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. / Desai, Jayesh; Shankar, Sridhar; Heinrich, Michael; Fletcher, Jonathan A.; Fletcher, Christopher D.; Manola, Judi; Morgan, Jeffrey A.; Corless, Christopher; George, Suzanne; Tuncali, Kemal; Silverman, Stuart G.; Van Den Abbeele, Annick D.; Van Sonnenberg, Eric; Demetri, George D.

In: Clinical Cancer Research, Vol. 13, No. 18, 15.09.2007, p. 5398-5405.

Research output: Contribution to journalArticle

Desai, J, Shankar, S, Heinrich, M, Fletcher, JA, Fletcher, CD, Manola, J, Morgan, JA, Corless, C, George, S, Tuncali, K, Silverman, SG, Van Den Abbeele, AD, Van Sonnenberg, E & Demetri, GD 2007, 'Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors', Clinical Cancer Research, vol. 13, no. 18, pp. 5398-5405. https://doi.org/10.1158/1078-0432.CCR-06-0858
Desai, Jayesh ; Shankar, Sridhar ; Heinrich, Michael ; Fletcher, Jonathan A. ; Fletcher, Christopher D. ; Manola, Judi ; Morgan, Jeffrey A. ; Corless, Christopher ; George, Suzanne ; Tuncali, Kemal ; Silverman, Stuart G. ; Van Den Abbeele, Annick D. ; Van Sonnenberg, Eric ; Demetri, George D. / Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 18. pp. 5398-5405.
@article{5a2d85d110b74575ae077fa1723666d5,
title = "Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors",
abstract = "Purpose: Resistance to imatinib mesylate is emerging as a clinical challenge in patients with metastatic gastrointestinal stromal tumors (GIST). Novel patterns of progression have been noted in a number of these patients. The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression. Experimental Design: Patients with metastatic GIST treated with imatinib were followed with serial computed tomography/magnetic resonance imaging and [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Where feasible, biopsies were done to document disease progression. Results: A total of 89 patients were followed for a median of 43 months. Forty-eight patients developed progressive disease. A unique {"}resistant clonal nodule{"} pattern (defined as a new enhancing nodular focus enclosed within a preexisting tumor mass) was seen in 23 of 48 patients and was thought to represent emergence of clones resistant to imatinib. Nodules were demonstrable a median of 5 months (range, 0-13 months) before objective progression defined by tumor size criteria and were the first sign of progression in 18 of 23 patients. Median survival among patients whose first progression was nodular was 35.1 months, compared with 44.6 months for patients whose first progression met Southwest Oncology Group criteria (P = 0.31). Comparative tumor biopsies were done in 10 patients at baseline and from progressing nodules. Genotypic analyses of KIT and PDGFRA kinases were done, revealing new activating kinase mutations in 80{\%} (8 of 10) of these patients. Conclusion: The resistant clonal nodule is a unique pattern of disease progression seen in patients with GISTs after an initial response to imatinib and reflects the emergence of imatinib-resistant clones. Conventional tumor measurements (Southwest Oncology Group/Response Evaluation Criteria in Solid Tumors) do not detect this subtle finding. A new enhancing nodule growing within a preexisting tumor mass should be classified as a new lesion and be regarded, at least, as partial progression of GIST.",
author = "Jayesh Desai and Sridhar Shankar and Michael Heinrich and Fletcher, {Jonathan A.} and Fletcher, {Christopher D.} and Judi Manola and Morgan, {Jeffrey A.} and Christopher Corless and Suzanne George and Kemal Tuncali and Silverman, {Stuart G.} and {Van Den Abbeele}, {Annick D.} and {Van Sonnenberg}, Eric and Demetri, {George D.}",
year = "2007",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-06-0858",
language = "English (US)",
volume = "13",
pages = "5398--5405",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors

AU - Desai, Jayesh

AU - Shankar, Sridhar

AU - Heinrich, Michael

AU - Fletcher, Jonathan A.

AU - Fletcher, Christopher D.

AU - Manola, Judi

AU - Morgan, Jeffrey A.

AU - Corless, Christopher

AU - George, Suzanne

AU - Tuncali, Kemal

AU - Silverman, Stuart G.

AU - Van Den Abbeele, Annick D.

AU - Van Sonnenberg, Eric

AU - Demetri, George D.

PY - 2007/9/15

Y1 - 2007/9/15

N2 - Purpose: Resistance to imatinib mesylate is emerging as a clinical challenge in patients with metastatic gastrointestinal stromal tumors (GIST). Novel patterns of progression have been noted in a number of these patients. The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression. Experimental Design: Patients with metastatic GIST treated with imatinib were followed with serial computed tomography/magnetic resonance imaging and [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Where feasible, biopsies were done to document disease progression. Results: A total of 89 patients were followed for a median of 43 months. Forty-eight patients developed progressive disease. A unique "resistant clonal nodule" pattern (defined as a new enhancing nodular focus enclosed within a preexisting tumor mass) was seen in 23 of 48 patients and was thought to represent emergence of clones resistant to imatinib. Nodules were demonstrable a median of 5 months (range, 0-13 months) before objective progression defined by tumor size criteria and were the first sign of progression in 18 of 23 patients. Median survival among patients whose first progression was nodular was 35.1 months, compared with 44.6 months for patients whose first progression met Southwest Oncology Group criteria (P = 0.31). Comparative tumor biopsies were done in 10 patients at baseline and from progressing nodules. Genotypic analyses of KIT and PDGFRA kinases were done, revealing new activating kinase mutations in 80% (8 of 10) of these patients. Conclusion: The resistant clonal nodule is a unique pattern of disease progression seen in patients with GISTs after an initial response to imatinib and reflects the emergence of imatinib-resistant clones. Conventional tumor measurements (Southwest Oncology Group/Response Evaluation Criteria in Solid Tumors) do not detect this subtle finding. A new enhancing nodule growing within a preexisting tumor mass should be classified as a new lesion and be regarded, at least, as partial progression of GIST.

AB - Purpose: Resistance to imatinib mesylate is emerging as a clinical challenge in patients with metastatic gastrointestinal stromal tumors (GIST). Novel patterns of progression have been noted in a number of these patients. The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression. Experimental Design: Patients with metastatic GIST treated with imatinib were followed with serial computed tomography/magnetic resonance imaging and [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Where feasible, biopsies were done to document disease progression. Results: A total of 89 patients were followed for a median of 43 months. Forty-eight patients developed progressive disease. A unique "resistant clonal nodule" pattern (defined as a new enhancing nodular focus enclosed within a preexisting tumor mass) was seen in 23 of 48 patients and was thought to represent emergence of clones resistant to imatinib. Nodules were demonstrable a median of 5 months (range, 0-13 months) before objective progression defined by tumor size criteria and were the first sign of progression in 18 of 23 patients. Median survival among patients whose first progression was nodular was 35.1 months, compared with 44.6 months for patients whose first progression met Southwest Oncology Group criteria (P = 0.31). Comparative tumor biopsies were done in 10 patients at baseline and from progressing nodules. Genotypic analyses of KIT and PDGFRA kinases were done, revealing new activating kinase mutations in 80% (8 of 10) of these patients. Conclusion: The resistant clonal nodule is a unique pattern of disease progression seen in patients with GISTs after an initial response to imatinib and reflects the emergence of imatinib-resistant clones. Conventional tumor measurements (Southwest Oncology Group/Response Evaluation Criteria in Solid Tumors) do not detect this subtle finding. A new enhancing nodule growing within a preexisting tumor mass should be classified as a new lesion and be regarded, at least, as partial progression of GIST.

UR - http://www.scopus.com/inward/record.url?scp=34848816032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848816032&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0858

DO - 10.1158/1078-0432.CCR-06-0858

M3 - Article

C2 - 17875769

AN - SCOPUS:34848816032

VL - 13

SP - 5398

EP - 5405

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -